Tofacitinib citrate 99%
3 Inquiries
540737-29-9
Pharmaceutical Grade
99%
SHANGHAI
1kg/1.3kg Carton
2060-01-28
Imatinib mesylate
-
Product Description
-
Seller Information
-
Inquiry History
-
Description
Properties
Melting point:201 °C (decomp)
storage temp. room temp
solubility DMSO: soluble5mg/mL (clear solution; warmed)
form powder
color white to beige
InChIKeySYIKUFDOYJFGBQ-YLAFAASESA-NBasic Info-
Product Name:
Tofacitinib citrate
Other Name:1-Piperidinepropanenitrile,4-methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-β-oxo-,(3R,4R)-,2-hydroxy-1,2,3-propanetricarboxylate (1:1);3-Piperidinamine,1-(cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-,(3R,4R)-,2-hydroxy-1,2,3-propanetricarboxylate (1:1);Tasocitinib citrate;CP 690500-10;Tofacitinib citrate;CP 690550-10;Xeljanz;Xeljanz XR
CAS No.:540737-29-9
Molecular Formula:C16H20N6O.C6H8O7
InChIKeys:InChIKey=SYIKUFDOYJFGBQ-YLAFAASESA-N
Molecular Weight:504.497
Exact Mass:504.196869
EC Number:1592732-453-0
HScode:29335990
Categories:
Characteristics-
PSA:
221
XLogP3:0.23418
Appearance:white to beige
Melting Point:201 °C (decomp)
Water Solubility:DMSO: soluble5mg/mL (clear solution; warmed)
Storage Conditions:room temp
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 4, Oral
Reproductive toxicity, Category 1B
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Danger
Hazard statement(s) H302 Harmful if swallowed
H360 May damage fertility or the unborn child
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P203 Obtain, read and follow all safety instructions before use.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
Response P301+P317 IF SWALLOWED: Get medical help.
P330 Rinse mouth.
P318 IF exposed or concerned, get medical advice.
Storage P405 Store locked up.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
Imatinib mesylate
-
Location:
No.21,HuanCheng West Road ,AnQing City ,Anhui Province,China
-
Payment Terms:
D/P,L/C,D/A
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2009
-
Certifications:
business license,ISO9001
ANHUI HAIKANG PHARMACEUTICAL CO.,LTD. was established in 2009 in Anqing City, Anhui Province. It is located along the north bank of mid and lower reaches of the Yangtze River. Enjoying favorable geographic superiorities and convenient transportation infrastructure: such as highway, high speed railway, airport, inland shipping container terminal and so on. By plane, it takes just 1 hour to Shanghai, 2 hours to Guangzhou or Beijing; by high speed train it takes 2 hours to reach Nanjing, 4 hours to Shanghai, 6.5 hours Beijing.Since founded the company has been committed to the production, sales and export of chemical raw materials of pharmaceutical APIs and intermediates, while as well as other services of product customization, process improvement, achievement transfer,etc.
The company covers an area of 28000 square meters. We invested 80 million Yuan to set up 3 synthesis workshops and 3 purification workshops, whose annual output value is over hundred million Yuan, and their profits and taxes are over 20 million Yuan. All our productions are in strict accordance with GMP standard and we have established a well-equipped R & D center.
Haikang currently employs 50 people. 2 of them are of doctoral degree, 6 of master degree,1 researcher returned from overseas and all the rest employees have at least college education. We have close cooperation with Zhejiang University of Technology, University of Science and Technology of China and Anhui University of Chinese Medicine ,etc. We have an academic advisors team consisting of experts and professors who have well background of medical profession and ample experience in pharmacy developing and marketing. It is a united, hard-working, courageous, rigorous and innovative team of elites.
Through years of unremitting efforts Haikang has made remarkable achievements in the R&D and production of anti-virus, antidiabetic series APIs and intermediates. The main products are ganciclovir, valganciclovir hydrochloride, valaciclovir HCL, silodosin, repaglinide, sitagliptin, imatinib and their intermediates. We have established long and stable relationship with nearly 100 domestic and international pharmaceutical manufacturers and research institutes.
To deal with increasingly fierce competition and challenges of economic globalization, Haikang adheres to the business philosophy of “Customer is First, Technology is Leading, Quality is Everything, Honesty for Development” and insists on developing scientifically, globally and diversely. Relying on our existing advantages, we focus on the integration of various resources, and actively optimize the system of decision-making, management and service. We keep up with the pace of the newest R&D trend in and outside China; keep continuous innovation to develop high-tech, market prospective products to satisfy different needs from different customers. While pursuing economic benefits, Haikang has also committed to spare no efforts to advanced environmental management. It is always a mission and moreover a responsibility for Haikang to take care of people’s health and protect the environment.
We have confidence in our future and looking forward to having sincere, win-win and brilliant cooperation with you!
-
-
Inquiry History3 Inquiries
Country Product Purchase Quantity Date Posted
Taiwan, China
Tofacitinib citrate
5 KG Dec 3, 2025
Canada
Tofactinib citrate
10 G Mar 21, 2025
India
Tofacitinib citrate
10 G Sep 26, 2025 Post an enquiry for this product